[ Ссылка ] - 1 in 3 will be diagnosed with cancer in our lifetime. The opportunity to add molecular and DNA screenings to our traditional routine cancer screenings is the future of medicine. Dr. Nadauld hopes precision medicine and precision health is the answer to how cancer is treated for all patients. Dr. Lincoln Nadauld, MD, PhD, is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare. His team is extending the lives and improving quality of life for late-stage cancer patients locally, nationally and internationally. Dr. Nadauld helped to develop technologies at Stanford University that identify DNA changes in cancer to predict whether or not a targeted cancer drug might be effective for a specific patient. Originally, from Utah, Dr. Nadauld attended Brigham Young University for his undergraduate degree and went on to complete medical and doctoral degrees followed by an internship and residency at the University of Utah. He completed a clinical fellowship in medical oncology and PhD at Stanford University where he continues to be involved in research collaborations. He was awarded the prestigious Young Investigator Award by the American Society of Clinical Oncology and the Career Development Award of the National Cancer Institute. His research has been featured in many publications, including the Journal of Oncology Practice, a publication of the American Society of Clinical Oncologists. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at [ Ссылка ]
